Grandfield & Dodd, LLC Iovance Biotherapeutics, Inc. Transaction History
Grandfield & Dodd, LLC
- $1.61 Billion
- Q2 2025
A detailed history of Grandfield & Dodd, LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 91,075 shares of IOVA stock, worth $191,257. This represents 0.01% of its overall portfolio holdings.
Number of Shares
91,075
Previous 90,975
0.11%
Holding current value
$191,257
Previous $302,000
48.34%
% of portfolio
0.01%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding IOVA
# of Institutions
292Shares Held
234MCall Options Held
1.14MPut Options Held
1.15M-
Mhr Fund Management LLC New York, NY29MShares$60.8 Million8.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA25.1MShares$52.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$44.6 Million0.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR11.8MShares$24.8 Million0.94% of portfolio
-
State Street Corp Boston, MA9.89MShares$20.8 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $331M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...